Radical cell therapy tested for lupus patients out of options
NCT ID NCT06189157
Summary
This early-stage trial is testing a new cell therapy called MB-CART19.1 for adults with severe systemic lupus that hasn't responded to standard treatments. The study aims to find a safe dose and see if the therapy can put lupus into remission. It involves genetically modifying a patient's own immune cells to target and reduce the harmful immune activity that drives the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Otto-von-Guericke-Universität Magdeburg
RECRUITINGMagdeburg, Germany
Contact
Contact
-
Universitatsklinikum Tubingen - Medizinische Universitätsklinik Abt. II
RECRUITINGTübingen, Germany
Contact
Contact
-
Universitätsklinikum Erlangen, Medizinische Klinik 3
NOT_YET_RECRUITINGErlangen, Germany
Contact
Contact
Conditions
Explore the condition pages connected to this study.